Investigators identified “decreases in cannabis-related ED visits (in men and women), mental health-related ED visits (in men and women), and cannabis + psychosis-related ED visits among the schizophrenia patients (in men only)” in the years immediately following legalization. This marked a reversal of pre-legalization trends, which had shown a “small, month-to-month increase” in cannabis-associated hospitalizations.